Similar articles

Abstract: Objective: To evaluate whether liposomal prostaglandin E1 (lipo-PGE1) can decrease reperfusion no-reflow in a catheter-based porcine model of acute myocardial infarction (AMI). Methods: Twenty-two male Chinese mini-swines were randomized into three groups: six in a sham-operation group, and eight each in the control and lipo-PGE1 groups. The distal part of the left anterior descending coronary artery (LAD) in the latter two groups was completely occluded for 2 h, and then reperfused for 3 h. Lipo-PGE1 (1 μg/kg) was injected 10 min before LAD occlusion until reperfusion for 1 h in the lipo-PGE1 group. Hemodynamic data and proinflammatory cytokines were examined before AMI, 2 h after occlusion, and 1, 2, and 3 h after reperfusion. Myocardial contrast echocardiography (MCE) and double staining were performed to evaluate the myocardial no-reflow area (NRA). Results: Left ventricular systolic pressure and end-diastolic pressure significantly improved in the lipo-PGE1 group after reperfusion compared with the control group and also 2 h after AMI (P<0.05 for both). MCE and double staining both showed that lipo-PGE1 decreased reperfusion NRA after AMI (P<0.05, P<0.01). Lipo-PGE1 decreased serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) after myocardial infarction reperfusion (P<0.05 for both). Conclusions: Lipo-PGE1 is cardioprotective in our porcine model of myocardial infarction reperfusion no-reflow, decreasing NRA and attenuating the inflammatory response.

[1]Fozzard, H.A., 1975. Validity of myocardial infarction models. Circulation, 52(6 Suppl.):III131-III146.

[2]He, Z.F., Li, Z.J., 2004. Prostaglandin E1 reduces reperfusion injury of myocardium by inhibiting cytokines production during cardiac surgery. J. Zhejiang Univ. (Med. Sci.), 33(4):353-356 (in Chinese).

[3]Jaffe, R., Charron, T., Puley, G., Dick, A., Strauss, B.H., 2008. Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation, 117(24):3152-3156.

[4]Kawamura, T., Nara, N., Kadosaki, M., Inada, K., Endo, S., 2000. Prostaglandin E1 reduces myocardial reperfusion injury by inhibiting proinflammatory cytokines production during cardiac surgery. Crit. Care Med., 28(7):2201-2208.

[5]Krombach, G.A., Kinzel, S., Mahnken, A.H., Gunther, R.W., Buecker, A., 2005. Minimally invasive close-chest method for creating reperfused or occlusive myocardial infarction in swine. Invest. Radiol., 40(1):14-18.

[6]Morishima, I., Sone, T., Okumura, K., Tsuboi, H., Kondo, J., Mukawa, H., Matsui, H., Toki, Y., Ito, T., Hayakawa, T., 2000. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J. Am. Coll. Cardiol., 36(4):1202-1209.

[7]Reffelmann, T., Sensebat, O., Birnbaum, Y., Stroemer, E., Hanrath, P., Uretsky, B.F., Schwarz, E.R., 2004. A novel minimal-invasive model of chronic myocardial infarction in swine. Coronary Artery Dis., 15(1):7-12.

[8]Smalling, R.W., Feld, S., Ramanna, N., Amirian, J., Felli, P., Vaughn, W.K., Swenson, C., Janoff, A., 1995. Infarct salvage with liposomal prostaglandin E1 administered by intravenous bolus immediately before reperfusion in a canine infarction-reperfusion model. Circulation, 92(4):935-943.

[9]Suzuki, Y., Lyons, J.K., Yeung, A.C., Ikeno, F., 2008. In vivo porcine model of reperfused myocardial infarction: in situ double staining to measure precise infarct area/area at risk. Catheter Cardiovasc. Interv., 71(1):100-107.

[10]Wang, J.A., Luo, R.H., Zhang, X., Xie, X.J., Hu, X.Y., He, A.N., Chen, J., Li, J.H., 2006. Bone marrow mesenchymal stem cell transplantation combined with perindopril treatment attenuates infarction remodeling in a rat model of acute myocardial infarction. J. Zhejiang Univ.-Sci. B, 7(8):641-647.